Skip to content
HomeLatest newsJanssen Pharmaceuticals releases a 2016 U.S. Transparency Report
A photo of a pharmacist holding a bottle of medicine

Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report

Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas, explains why Janssen is sharing information around its medication pricing and other business practices.

Johnson & Johnson has a legacy of leadership when it comes to transparency. And the Janssen Pharmaceutical Companies of Johnson & Johnson recognize that consumers in the U.S. are particularly concerned about the high cost of healthcare these days. That’s why the company just released a 2016 U.S. Transparency Report that includes information on pricing and other business practices, covering everything from discovery to the commercialization of pharmaceuticals.

“Our hope is that this report will address questions people may have, and that it will lead to more discussion about how we can work together to move toward a more value-based healthcare system—one that delivers what we all want: greater access to care at a more manageable cost, and, most importantly, better health for us all,” says Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas.

Watch this video of Taubert to learn more about the 2016 U.S. Transparency Report and how it can help better inform consumers.

hqdefault.jpg
2016 U.S. Transparency Report Jennifer Taubert

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.